Rifapentine + Isoniazid
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Latent Tuberculosis
Conditions
Latent Tuberculosis
Trial Timeline
Oct 12, 2019 → May 15, 2025
NCT ID
NCT03730181About Rifapentine + Isoniazid
Rifapentine + Isoniazid is a phase 1/2 stage product being developed by Sanofi for Latent Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03730181. Target conditions include Latent Tuberculosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03730181 | Phase 1/2 | Completed |
Competing Products
2 competing products in Latent Tuberculosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Doravirine (DOR) + Rifapentine (RPT) + Isoniazid (INH) | Merck | Phase 1 | 33 |
| NovoMix 30 + Tablet treatment | Novo Nordisk | Pre-clinical | 22 |